Effectiveness and safety of immune response to SARS‑CoV‑2 vaccine in patients with chronic kidney disease and dialysis: A systematic review and meta‑analysis
- Authors:
- Kejia Li
- Yang Xia
- Hua Ye
- Xian Sun
- Bairu Shi
- Jiajun Wu
-
Affiliations: Department of Nephrology, The First People's Hospital of Jiashan, Jiaxing, Zhejiang 314100, P.R. China - Published online on: March 19, 2024 https://doi.org/10.3892/br.2024.1766
- Article Number: 78
-
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
|
Vallée A: Geoepidemiological perspective on COVID-19 pandemic review, an insight into the global impact. Front Public Health. 11(1242891)2023.PubMed/NCBI View Article : Google Scholar | |
|
Khoury DS, Docken SS, Subbarao K, Kent SJ, Davenport MP and Cromer D: Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat Med. 29:574–578. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Carabelli AM, Peacock TP, Thorne LG, Harvey WT and Hughes J: COVID-19 Genomics UK Consortium. Peacock SJ, Barclay WS, de Silva TI, Towers GJ and Robertson DL: SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat Rev Microbiol. 21:162–177. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Bouhaddou M, Reuschl AK, Polacco BJ, Thorne LG, Ummadi MR, Ye C, Rosales R, Pelin A, Batra J, Jang GM, et al: SARS-CoV-2 variants evolve convergent strategies to remodel the host response. Cell. 186:4597–4614.e26. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Jiang S, Xia S, Ying T and Lu L: A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. Cell Mol Immunol. 17(554)2020.PubMed/NCBI View Article : Google Scholar | |
|
Qualls N, Levitt A, Kanade N, Wright-Jegede N, Dopson S, Biggerstaff M, Reed C and Uzicanin A: CDC Community Mitigation Guidelines Work Group. Community mitigation guidelines to prevent pandemic influenza-United States, 2017. MMWR Recomm Rep. 66:1–34. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Farsalinos K, Poulas K, Kouretas D, Vantarakis A, Leotsinidis M, Kouvelas D, Docea AO, Kostoff R, Gerotziafas GT, Antoniou MN, et al: Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare. Toxicol Rep. 8:1–9. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Li H, Burm SW, Hong SH, Ghayda RA, Kronbichler A, Smith L, Koyanagi A, Jacob L, Lee KH and Shin JI: A comprehensive review of coronavirus disease 2019: Epidemiology, transmission, risk factors, and international responses. Yonsei Med J. 62:1–11. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L and Remuzzi G: Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 17:46–64. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wu VC, Hsueh PR, Lin WC, Huang JW, Tsai HB, Chen YM and Wu KD: SARS Research Group of the National Taiwan University College of Medicine and National University Hospital. Acute renal failure in SARS patients: More than rhabdomyolysis. Nephrol Dial Transplant. 19:3180–3182. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Cha RH, Joh JS, Jeong I, Lee JY, Shin HS, Kim G and Kim Y: Critical Care Team of National Medical Center. Renal complications and their prognosis in Korean patients with Middle East respiratory syndrome-coronavirus from the central MERS-CoV designated hospital. J Korean Med Sci. 30:1807–1814. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Chan JFW, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, et al: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 395:514–523. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Gansevoort RT and Hilbrands LB: CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol. 16:705–706. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Pakhchanian H, Raiker R, Mukherjee A, Khan A, Singh S and Chatterjee A: Outcomes of COVID-19 in CKD patients: A multicenter electronic medical record cohort study. Clin J Am Soc Nephrol. 16:785–786. 2021.PubMed/NCBI View Article : Google Scholar | |
|
ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: A call to action by the ERA-EDTA. Nephrol Dial Transplant. 36:87–94. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Bajwa H, Riaz Y, Ammar M, Farooq S and Yousaf A: The dilemma of renal involvement in COVID-19: A systematic review. Cureus. 12(e8632)2020.PubMed/NCBI View Article : Google Scholar | |
|
Go AS, Chertow GM, Fan D, McCulloch CE and Hsu C: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 351:1296–1305. 2004.PubMed/NCBI View Article : Google Scholar | |
|
O'Callaghan KP, Blatz AM and Offit PA: Developing a SARS-CoV-2 vaccine at warp speed. JAMA. 324:437–438. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Calina D, Hartung T, Docea AO, Spandidos DA, Egorov AM, Shtilman MI, Carvalho F and Tsatsakis A: COVID-19 vaccines: Ethical framework concerning human challenge studies. Daru. 28:807–812. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sharpe HR, Gilbride C, Allen E, Belij-Rammerstorfer S, Bissett C, Ewer K and Lambe T: The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology. 160:223–232. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al: ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 355(i4919)2016.PubMed/NCBI View Article : Google Scholar | |
|
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP and Thomas J: Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 10(ED000142)2019.PubMed/NCBI View Article : Google Scholar | |
|
Wan X, Wang W, Liu J and Tong T: Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 14(135)2014.PubMed/NCBI View Article : Google Scholar | |
|
Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D, Rozen-Zvi B and Zingerman B: Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients-a prospectivecohort study. Nephrol Dial Transplant. 11(gfab155)2021.PubMed/NCBI View Article : Google Scholar | |
|
Broseta JJ, Rodríguez-Espinosa D, Soruco E and Maduell F: Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients. Nephrol Dial Transplant. 36:1754–1755. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Labriola L, Scohy A, Van Regemorter E, Robert A, Clerbaux G, Gillerot G, Pochet JM, Biller P, De Schuiteneer M, Morelle J, et al: Immunogenicity of BNT162b2 SARS-CoV-2 vaccine in a multicenter cohort of nursing home residents receiving maintenance hemodialysis. Am J Kidney Dis. 78:766–768. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Lesny P, Anderson M, Cloherty G, Stec M, Haase-Fielitz A, Haarhaus M, Santos C, Lucas C, Macario F and Haase M: Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: A multicenter prospective observational pilot study. J Nephrol. 34:975–983. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B, Del Bello A, Marion O, Faguer S, Izopet J and Kamar N: High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant. 36:1704–1709. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Rincon-Arevalo H, Choi M, Stefanski AL, Halleck F, Weber U, Szelinski F, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A, et al: Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 6(eabj1031)2021.PubMed/NCBI View Article : Google Scholar | |
|
Sattler A, Schrezenmeier E, Weber UA, Potekhin A, Bachmann F, Straub-Hohenbleicher H, Budde K, Storz E, Proß V, Bergmann Y, et al: Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 131(e150175)2021.PubMed/NCBI View Article : Google Scholar | |
|
Schrezenmeier E, Bergfeld L, Hillus D, Lippert JD, Weber U, Tober-Lau P, Landgraf I, Schwarz T, Kappert K, Stefanski AL, et al: Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis. Front Immunol. 12(690698)2021.PubMed/NCBI View Article : Google Scholar | |
|
Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S and Kirsch B: Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant. 36:1709–1716. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Speer C, Benning L, Töllner M, Nusshag C, Kälble F, Reichel P, Schaier M, Bartenschlager M, Schnitzler P, Zeier M, et al: Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2. Kidney Int. 100:700–702. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Speer C, Morath C, Töllner M, Buylaert M, Göth D, Nusshag C, Kälble F, Schaier M, Grenz J, Kreysing M, et al: Humoral responses to single-dose BNT162b2 mRNA vaccination in dialysis patients previously infected with SARS-CoV-2. Front Med (Lausanne). 8(721286)2021.PubMed/NCBI View Article : Google Scholar | |
|
Strengert M, Becker M, Ramos GM, Dulovic A, Gruber J, Juengling J, Lürken K, Beigel A, Wrenger E, Lonnemann G, et al: Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. EBioMedicine. 70(103524)2021.PubMed/NCBI View Article : Google Scholar | |
|
Cserep G, Morrow D, Latchford K, Jesset R, Dosa A and Kirmizis D: The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: A single-centre study. Clin Exp Nephrol. 26:54–58. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, Faulhaber-Walter R, Schewe J, Martin H, Schirutschke H, et al: Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Heal Eur. 9(100178)2021.PubMed/NCBI View Article : Google Scholar | |
|
Torreggiani M, Blanchi S, Fois A, Fessi H and Piccoli GB: Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: The war is far from being won. Kidney Int. 99:1494–1496. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Tylicki L, Biedunkiewicz B, Dąbrowska M, Ślizień W, Tylicki P, Polewska K, Rosenberg I, Rodak S and Dębska-Ślizień A: Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19: The COViNEPH project. Polish Arch Intern Med. 131:797–801. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Weigert A, Bergman ML, Gonçalves LA, Godinho I, Duarte N, Abrantes R, Borges P, Brennand A, Malheiro V, Matoso P, et al: Longitudinal analysis of antibody responses to the mRNA BNT162b2 vaccine in patients undergoing maintenance hemodialysis: A 6-month follow-up. Front Med (Lausanne). 8(796676)2021.PubMed/NCBI View Article : Google Scholar | |
|
Yanay NB, Freiman S, Shapira M, Wishahi S, Hamze M, Elhaj M, Zaher M and Armaly Z: Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients. Kidney Int. 99:1496–1498. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, Benda MA, Sprenger-Mähr H, Winder T and Lhotta K: The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in Hemodialysis patients. Front Immunol. 12(704773)2021.PubMed/NCBI View Article : Google Scholar | |
|
Alkadi MM, Hamad A, Ghazouani H, Elshirbeny M, Ali MY, Ghonimi T, Ibrahim R, Abuhelaiqa E, Abou-Samra AB, Al-Malki H and Butt AA: Effectiveness of messenger RNA vaccines against SARS-CoV-2 infection in hemodialysis patients: A case-control study. Vaccines (Basel). 11(49)2022.PubMed/NCBI View Article : Google Scholar | |
|
Ben-Dov IZ, Oster Y, Tzukert K, Alster T, Bader R, Israeli R, Asayag H, Aharon M, Burstein I, Pri-Chen H, et al: Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-up. J Nephrol. 35:153–164. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Bielopolski D, Libresco G, Barda N, Dagan N, Steinmetz T, Yahav D, Charytan DM, Balicer RD and Rozen-Zvi B: BNT162b2 vaccine effectiveness in chronic kidney disease patients-an observational study. Clin Kidney J. 15:1838–1846. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Butt AA, Talisa VB, Yan P, Shaikh OS, Omer SB and Mayr FB: Real-World effectiveness of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) mRNA vaccines in preventing confirmed infection in patients on chronic hemodialysis. Clin Infect Dis. 75:e617–e622. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Duarte R, Roldão M, Figueiredo C, Luz I, Ferrer F, Gonçalves H, Sofia F and Lopes K: Humoral response to BNT162b2 mRNA COVID-19 vaccine in peritoneal and hemodialysis patients: A comparative study. Ther Apher Dial. 26:790–796. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Davidovic T, Schimpf J, Abbassi-Nik A, Stockinger R, Sprenger-Mähr H, Lhotta K and Zitt E: Humoral and cellular immune response after a 3-dose heterologous SARS-CoV-2 vaccination using the mRNA-BNT162b2 and viral vector Ad26COVS1 vaccine in hemodialysis patients. Front Immunol. 13(907615)2022.PubMed/NCBI View Article : Google Scholar | |
|
Quiroga B, Soler MJ, Ortiz A, Vaquera SM, Mantecón CJ, Useche G, Márquez MG, Carnerero M, Rodríguez MT, Ramos PM, et al: Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: The SENCOVAC study. Nephrol Dial Transplant. 37:1868–1878. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Trakarnvanich T, Ngamvichchukorn T, Phumisantiphong U, Pholtawornkulchai K, Phochanasomboon K and Manomaipiboon A: Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant. Vaccine. 40:6499–6511. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Ducloux D, Colladant M, Chabannes M, Yannaraki M and Courivaud C: Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int. 100:702–704. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E, Chalencon E, Mathias V, Ovize A, Cart-Tanneur E, et al: The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int. 100:928–936. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Fernando E and Govindan S: Neutralizing SARS-CoV-2 antibody response and protective effect of 2 Doses of ChAdOx1 nCoV-19 and BBV152 vaccines in hemodialysis patients: A preliminary report. Kidney Int Rep. 6:2521–2522. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Frantzen L, Cavaille G, Thibeaut S and El-Haik Y: Efficacy of the BNT162b2 mRNA Covid-19 vaccine in a hemodialysis cohort. Nephrol Dial Transplant. 36:1756–1757. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Goupil R, Benlarbi M, Beaubien-Souligny W, Nadeau-Fredette AC, Chatterjee D, Goyette G, Gunaratnam L, Lamarche C, Tom A, Finzi A, et al: Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. CMAJ. 193:E793–E800. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Clavero R, Parra-Lucares A, Méndez-Valdés G, Villa E, Bravo K, Mondaca E, Aranda J, Brignardello R, Gajardo C, Ordenes A, et al: Humoral immune response of BNT162b2 and coronavac vaccinations in hemodialysis patients: A multicenter prospective cohort. Vaccines (Basel). 10(1542)2022.PubMed/NCBI View Article : Google Scholar | |
|
Liu W, Zhou L, Yin W, Wang J and Zuo X: Global, regional, and national burden of chronic kidney disease attributable to high sodium intake from 1990 to 2019. Front Nutr. 10(1078371)2023.PubMed/NCBI View Article : Google Scholar | |
|
Kovesdy CP: Epidemiology of chronic kidney disease: An update 2022. Kidney Int Suppl (2011). 12:7–11. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, Lameire NH and Eknoyan G: Clinical practice guidelines for Anemia in chronic kidney disease: Problems and solutions. A position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 74:1237–1240. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Zou X, Chen K, Zou J, Han P, Hao J and Han Z: Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 14:185–192. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, Tan Y, Wang H, Wang C, Liu L, et al: Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 12(2506)2021.PubMed/NCBI View Article : Google Scholar | |
|
Martinez-Rojas MA, Vega-Vega O and Bobadilla NA: Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol. 318:F1454–F1462. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sanhueza ME, Martín PS, Brantes L, Caro S, Carrasco G and Machuca E: Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis. Hum Vaccin Immunother. 19(2173904)2023.PubMed/NCBI View Article : Google Scholar | |
|
Hou YC, Lu KC and Kuo KL: The efficacy of COVID-19 vaccines in chronic kidney disease and kidney transplantation patients: A narrative review. Vaccines (Basel). 9(885)2021.PubMed/NCBI View Article : Google Scholar | |
|
Rossi M, Pessolano G and Gambaro G: What has vaccination against COVID-19 in CKD patients taught us? J Nephrol. 36:1257–1266. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Martins MP and de Oliveira RB: COVID-19 and chronic kidney disease: A narrative review. COVID. 3:1092–1105. 2023. | |
|
Babel N, Hugo C and Westhoff TH: Vaccination in patients with kidney failure: Lessons from COVID-19. Nat Rev Nephrol. 18:708–723. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Jiang Z, Liu J, Geng L, Zhong Z, Tan J, Wen D, Zhou L, Tang Y and Qin W: The influences of COVID-19 on patients with chronic kidney disease: A multicenter cross-sectional study. Front Psychiatry. 12(754310)2021.PubMed/NCBI View Article : Google Scholar | |
|
Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A, Tau N, Mashraki T, Nesher E and Rahamimov R: Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: A prospective cohort study. Clin Microbiol Infect. 27:1173.e1–1173.e4. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Kunutsor SK and Laukkanen JA: Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis. J Infect. 82:159–198. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Bohn MK, Loh TP, Wang CB, Mueller R, Koch D, Sethi S, Rawlinson WD, Clementi M, Erasmus R, Leportier M, et al: IFCC interim guidelines on serological testing of antibodies against SARS-CoV-2. Clin Chem Lab Med. 58:2001–2008. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ma BM, Tam AR, Chan KW, Ma MKM, Hung IFN, Yap DYH and Chan TM: Immunogenicity and safety of COVID-19 vaccines in patients receiving renal replacement therapy: A systematic review and meta-analysis. Front Med (Lausanne). 9(827859)2022.PubMed/NCBI View Article : Google Scholar | |
|
Javadinia SA, Alizadeh K, Mojadadi MS, Nikbakht F, Dashti F, Joudi M, Harati H, Welsh JS, Farahmand SA and Attarian F: COVID-19 vaccination in patients with malignancy; a systematic review and meta-analysis of the efficacy and safety. Front Endocrinol (Lausanne). 13(860238)2022.PubMed/NCBI View Article : Google Scholar | |
|
Joudi M, Binabaj MM, Porouhan P, PeyroShabany B, Tabasi M, Fazilat-Panah D, Khajeh M, Mehrabian A, Dehghani M, Welsh JS, et al: A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer; does trastuzumab interfere with the outcome? Front Endocrinol (Lausanne). 13(798975)2022.PubMed/NCBI View Article : Google Scholar | |
|
Ciarambino T, Para O and Giordano M: Immune system and COVID-19 by sex differences and age. Womens Health (Lond). 17(17455065211022262)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ho JQ, Sepand MR, Bigdelou B, Shekarian T, Esfandyarpour R, Chauhan P, Serpooshan V, Beura LK, Hutter G and Zanganeh S: The immune response to COVID-19: Does sex matter? Immunology. 166:429–443. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY, Touizer E, Meng B and Abdullahi A: CITIID-NIHR BioResource COVID-19 Collaboration. Elmer A, et al: Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 596:417–422. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Chen Q, Zhao H, Yao X, Lin Z, Li J, Lin B, Wang R, Huang Y, Su Y, Wu T, et al: Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. Vaccine. 38:6096–6102. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Fernandes M da CR, Vasconcelos GS, de Melo ACL, Matsui TC, Caetano LF, de Carvalho Araújo FM and Fonseca MHG: Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review. Mol Immunol. 156:148–155. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Zheng YY, Ma YT, Zhang JY and Xie X: COVID-19 and the cardiovascular system. Nat Rev Cardiol. 17:259–260. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, de Silva TI, Murray SM, Rea D, Snowden JA, Carroll M, et al: SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nat Med. 29:1760–1774. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Letizia AG, Ge Y, Vangeti S, Goforth C, Weir DL, Kuzmina NA, Balinsky CA, Chen HW, Ewing D, Soares-Schanoski A, et al: SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: A prospective cohort study. Lancet Respir Med. 9:712–720. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Brüssow H: COVID-19: Vaccination problems. Environ Microbiol. 23:2878–2890. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Sáez-Peñataro J, Torres F, Bartra J, Bascuas J, Vilella A, Tortajada M, Quesada S, González E, López-Suñé E, Castells A, et al: Tolerability and reactogenicity profile of mRNA SARS-Cov-2 vaccines from a mass vaccination campaign in a tertiary hospital: Between-vaccine and between-population prospective observational study (VigilVacCOVID Study). BioDrugs. 36:509–520. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Al-Sadeq DW, Shurrab FM, Ismail A, Amanullah FH, Thomas S, Aldewik N, Yassine HM, Rahim HF, Abu-Raddad L and Nasralla GK: Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals. J Travel Med. 28(taab190)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, Omori K, Akita T, Shigemoto N, Tanaka J and Ohge H: Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J Infect Chemother. 28:576–581. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Hulme WJ, Horne EMF, Parker EPK, Keogh RH, Williamson EJ, Walker V, Palmer TM, Curtis HJ, Walker AJ, Andrews CD, et al: Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: Matched cohort study in OpenSAFELY-TPP. BMJ. 380(e072808)2023.PubMed/NCBI View Article : Google Scholar | |
|
Ono S, Michihata N, Yamana H, Uemura K, Ono Y, Jo T and Yasunaga H: Comparative effectiveness of BNT162b2 and mRNA-1273 booster dose after BNT162b2 primary vaccination against the omicron variants: A retrospective cohort study using large-scale population-based registries in Japan. Clin Infect Dis. 76:18–24. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Puspitasari M, Sattwika PD, Rahari DS, Wijaya W, Hidayat ARP, Kertia N, Purwanto B and Thobari JA: Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: A prospective cohort study. Sci Rep. 13(11557)2023.PubMed/NCBI View Article : Google Scholar | |
|
Mehta N, Shah S, Paudel K, Chamlagain R and Chhetri S: Safety and efficacy of coronavirus disease-19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review. Heal Sci Rep. 5(e700)2022.PubMed/NCBI View Article : Google Scholar | |
|
Wang Y, Yang L and Xu G: New-onset acute interstitial nephritis Post-SARS-CoV-2 infection and COVID-19 vaccination: A panoramic review. J Epidemiol Glob Health. 13:615–636. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Zhang S, He J, Tang B, Zhou Q, Hu Y, Yu Y, Chen J, Liu Y, Li C, Ren H and Liao X: Cellular and humoral responses to recombinant and inactivated SARS-CoV-2 vaccines in CKD Patients: An observational study. J Clin Med. 12(1225)2023.PubMed/NCBI View Article : Google Scholar | |
|
Qaderi K, Golezar MH, Mardani A, Mallah MA, Moradi B, Kavoussi H, Shamsabadi A and Golezar S: Cutaneous adverse reactions of COVID-19 vaccines: A systematic review. Dermatol Ther. 35(e15391)2022.PubMed/NCBI View Article : Google Scholar | |
|
Tan SW, Tam YC and Pang SM: Cutaneous reactions to COVID-19 vaccines: A review. JAAD Int. 7:178–186. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Sharif N, Alzahrani KJ, Ahmed SN and Dey SK: Efficacy, immunogenicity and safety of COVID-19 vaccines: A systematic review and meta-analysis. Front Immunol. 12(714170)2021.PubMed/NCBI View Article : Google Scholar | |
|
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al: Effect of an inactivated vaccine Against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA. 324:951–960. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, Zou H and Sun C: Safety of SARS-CoV-2 vaccines: A systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 10(94)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, Salmon D and Yu H: Evaluation of the safety profile of COVID-19 vaccines: A rapid review. BMC Med. 19(173)2021.PubMed/NCBI View Article : Google Scholar |
